Search for Clinical Trial Results

Nerve Sheath Neoplasms - 21 Studies Found
Status | Study |
Terminated |
Study Name: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas Condition: Neurofibroma Date: 2008-07-14 Interventions: Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |
Terminated |
Study Name: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas Condition: Cutaneous Neurofibromas Date: 2009-06-15 Interventions: Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Active, not recruiting |
Study Name: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas Condition:
Date: 2010-06-08 Interventions: Drug: Gleevec Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with |
Active, not recruiting |
Study Name: Study of PEG-Intron for Plexiform Neurofibromas Condition: Plexiform Neurofibroma Date: 2006-11-02 Interventions: Drug: PEG-Intron |
Completed |
Study Name: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas Condition: Plexiform Neurofibromas Date: 2014-06-25 Interventions: Drug: Imatinib Mesylate oral administration Other Na |
Terminated |
Study Name: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) Condition: Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 Date: 2011-05-27 Interventions: Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Completed |
Study Name: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 Condition:
Date: 2008-03-27 Interventions: Drug: Ranibizumab Given as an injection into three cutaneous neurofibromas on day 1 of the study treatme |
Completed |
Study Name: Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 Condition:
Date: 2006-04-11 |
Completed |
Study Name: Topical Imiquimod 5% Cream for Treatment of Cutaneous Neurofibromas in Adults With Neurofibromatosis 1 Condition:
Date: 2009-03-17 Interventions: Drug: Imiquimod 5% Cream Applied topically to three tumors 5 times per week for a full 6 weeks |
Active, not recruiting |
Study Name: Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 Condition:
Date: 2017-03-08 Interventions:
|